Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Geriatric Population
4.2.2 Increase in Adoption of Immunoglobulin Treatment
4.2.3 Growth in Prevalence of Immunodeficiency Diseases and Bleeding Disorders
4.3 Market Restraints
4.3.1 Stringent Government Regulations
4.3.2 High Cost of Therapy
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 IgG
5.1.2 IgA
5.1.3 IgM
5.1.4 IgE
5.1.5 IgD
5.2 By Application
5.2.1 Hypogammaglobulinemia
5.2.2 Chronic Inflammatory Demyelinating polyneuropathy (CIDP)
5.2.3 Primary Immunodeficiency Diseases
5.2.4 Myasthenia Gravis
5.2.5 Multifocal Motor Neuropathy
5.2.6 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bio Products Laboratory Ltd.
6.1.2 Biotest AG
6.1.3 China Biologic Products Holdings, Inc.
6.1.4 CSL Behring
6.1.5 Grifols, S.A.
6.1.6 Kedrion S.p.A
6.1.7 LFB SA and Shanghai RAAS Blood Products Co., Ltd.
6.1.8 Octapharma
6.1.9 Takeda Pharmaceutical Company Limited


7 MARKET OPPORTUNITIES AND FUTURE TRENDS